Literature DB >> 14580761

Primary hyperparathyroidism: controversies in surgical management.

Geeta Lal1, Orlo H Clark.   

Abstract

Controversy surrounds the optimal management of patients with mild or asymptomatic primary hyperparathyroidism (PHPT). Although many new medical therapies for this disorder have emerged in the past decade, existing evidence indicates that parathyroidectomy is the only curative option and reverses not only many of the classic, but also the more subtle, manifestations of PHPT. Moreover, parathyroidectomy can be performed successfully with minimal morbidity by experienced surgeons. With the recent development and widespread use of several preoperative localization studies, various focused approaches to neck exploration and intraoperative parathyroid hormone testing, management for this disorder will need to be tailored to individual patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580761     DOI: 10.1016/j.tem.2003.09.001

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  3 in total

Review 1.  What symptom improvement can be expected after operation for primary hyperparathyroidism?

Authors:  Nadine R Caron; Janice L Pasieka
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

2.  Impact of adenoma weight and ectopic location of parathyroid adenoma on localization study results.

Authors:  Yeşim Erbil; Umut Barbaros; Mustafa Tükenmez; Halim Işsever; Artür Salmaslioğlu; Işik Adalet; Selçuk Ozarmağan; Serdar Tezelman
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

3.  Meeting report of the "Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017".

Authors:  Agnieszka Pozdzik; Naim Maalouf; Emmanuel Letavernier; Isabelle Brocheriou; Jean-Jacques Body; Benjamin Vervaet; Carl Van Haute; Johanna Noels; Romy Gadisseur; Vincent Castiglione; Frédéric Cotton; Giovanni Gambaro; Michel Daudon; Khashayar Sakhaee
Journal:  J Nephrol       Date:  2019-01-24       Impact factor: 3.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.